



AcouSort AB (publ)
Press release 25 October 2023

High throughput cell wash for cell therapy - an important milestone towards new OEM partnerships

AcouSort's strategy is to develop and deliver automated cell processing OEM modules that replaces several of today's manual handling steps. The newly developed high throughput cell processing test system is directed toward the cell therapy manufacturing process and can contribute making the process more efficient and safer. The cell therapy components are for single use, which means that AcouSort sees great opportunities in establishing a significant stream of recurring revenue over time.

As previously communicated, AcouSort has developed a new test system for automated cell handling within cell therapy. Recently, AcouSort published an application note with proof-of-concept data demonstrating that the system performance meets important requirements for cell therapy applications. The new data show up-concentration and washing of target cells at ten times higher flow rates in a single chip than what has been possible with AcouSort's prior solutions. In the test system it was also demonstrated that throughput could be further increased by parallelizing separation chips.

AcouSort's partnering company within cell therapy manufacturing is currently evaluating the test system and in parallel AcouSort will continue its internal application development to produce additional data further validating the performance. AcouSort also sees opportunities to transfer this technological advancement of significantly increased throughput to more areas by using the system for other separation-based OEM applications.

"The improved performance is a significant milestone in our strategic efforts to commercially target the cell therapy sector. We now have solid proof that our solution is relevant for this market, and that we are moving towards the development of a new OEM product," says Jessica Congiu, Commercial Product Manager at AcouSort.

FOR FURTHER INFORMATION ON ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank.